


ADVANCE YOUR CELL THERAPY

with our cross-platform capabilities



CellCarta

Modification/
Selection of cells

**Achieving the Next Level in
Product Characterization**

**Monitoring Your Product
and Its Therapeutic
Response with
Biomarker Analysis**

Isolation
of cells

**Improving Patient
Selection Using
Complementary
Platforms**

Infusion
of cells

**Evaluating
Combination
Therapy**

Lymphodepletion

Combination therapy

**Simplifying
Toxicity
Assessment**

Monitoring toxicity

**>150 COMPLETED
AND ONGOING
PROJECTS IN CELL THERAPY**

400+ SCIENTISTS

**20+ YEARS
OF BIOMARKER AND
ASSAY EXPERTISE**

**105 SITES IN
COUNTRIES**

Achieving the Next Level in Product Characterization

Genomic profiling of target cells

- Targeted RNA profiling
- NGS – TCR sequencing
- qPCR
- Single-cell RNA sequencing

Cellular profiling

- Flow cytometry/CyTOF
 - From absolute cell count to functionality by ICS
 - Customized construct-specific panels
- MSD® and ELISpot/FluoroSpot

Improving Patient Selection Using Complementary Platforms

Characterization of patients' inflammatory state

- Flow cytometry: immune profiling panels, lymphodepletion (TBNK)
- MSD®: cytokine profiling

Tracking key genetic biomarkers

- qPCR: key mutations
- NGS - TSO500 panel by Illumina: key tumor biomarkers, MSI, TMB
- Targeted RNA profiling

Monitoring tumor targets

- IHC: key biomarkers including MAGE4, NY-ESO-1, CD19, CD22, CD123, BCMA
- Mass spectrometry: soluble and FFPE BCMA

Monitoring previous treatments

- ELISA: detection of rituximab

Monitoring Your Product and Its Therapeutic Response with Biomarker Analysis

Tracking transgene or engineered cell

- Targeted RNA profiling
- NGS – TCR sequencing
- qPCR – preceded or not by cell sorting (FACS)
- Single-cell RNA sequencing

Immune profiling/cellular kinetics

- Flow cytometry: absolute cell counts (proliferation panels - TBNK), surface profiling - including immune checkpoints (PD-1, TIM-3, LAG-3), activation/exhaustion markers, ICS assays
- IHC (single-plex and multiplex): tissue biomarkers for T-cell activation/exhaustion, antigen presentation, immune infiltration, TME

Tracking remaining tumor cells or tumor-specific targets

- Mass spectrometry: BCMA
- IHC
- Flow cytometry

Evaluating Combination Therapy

Pharmacokinetics (PK) of other biologics

- MSD®
- ELISA

Simplifying Toxicity Assessment

Measurement of cytokine release syndrome (CRS)

- MSD®
- ELISA

NGS: Next Generation Sequencing, TCR: T-cell receptor, ICS: intracellular cytokine staining, MSD®: Meso Scale Discovery®, MSI: microsatellite instability, TMB: tumor mutational burden, IHC: immunohistochemistry

For more information on how CellCarta can partner with you, please contact us:

www.cellcarta.com
info@cellcarta.com
Toll Free: + 1 877 776 3443

HEADQUARTERS

201 President Kennedy Ave., Suite 3900
Montreal, Quebec, Canada H2X 3Y7
Phone: + 1 514 360 3600